CEL-SCI reports recent data review by IDMC for pivotal phase 3 head and neck cancer study
CEL-SCI announced the IDMC for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its review of the Phase 3 study data. The IDMC saw no evidence of any significant safety questions. December 07, 2017